Remdesivir API

Name	Remdesivir
Chinese name	瑞德西韦
Cas Number	1809249-37-3
Source	India
Qualifications	-/-/-/-/-

Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new coronavirus drugs. The country’s first officially approved drug for the treatment of new coronavirus-related diseases is given priority to severely ill patients. Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its market prospects are very broad, and it has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in vitro and in vivo in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS ) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.

Hot Tags: remdesivir api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Canagliflozin API, Tippyridine Hydrochloride API, Edoxaban API, Gabapentin API, Rasagiline Mesylate API, Perindopril Arginine API

• Previous: Bromocriptine Mesylate API
• Next: Phenylephrine Hydrochloride API